PUBLIC COMPANY
saveBeeline Medicines Corp
updated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
🐶 Hiring Signal
News
- 8 companies hiring in North Carolina nowLooking for a biopharma role in North Carolina? Jobs on BioSpace increased significantly year over year in October. Check out the open positions posted now for life sciences professionals like you.biospace · 2d ago
- Beeline reveals Phase 2 lupus data from old Bristol Myers drugBeeline Medicines fleshed out an impressive mid-stage win in systemic lupus on Wednesday, setting the stage for Phase 3 trials with a former drug from Bristol Myers Squibb. At each of three doses t…endpoints · 9d ago
- BioSpace 2027 Best Places to Work shines light on most admired employersThe list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.biospace · 10d ago
- The top 12 companies hiring in biopharma nowAverage jobs live on BioSpace increased year over year in October, a good sign for those eyeing a new position. If that’s you, check out the list of which companies are most actively looking to hire.biospace · 15d ago
- Dren Bio lands $350M to push rare blood cancer therapy toward marketAfter Sanofi paid $600 million in cash to acquire Dren Bio’s bispecific last year, the biotech has secured a hefty financing to fund late-stage development and commercial preparations for its lead…biospace · 22d ago
- Beeline Medicines reports promising Phase 2 lupus dataThe business of advancing shelved pharma assets continues to reap benefits, this time for Beeline Medicines and a lupus candidate provided by Bristol Myers Squibb. The buzzy Bain-backed startup sai…endpoints · 2mo ago
- Beeline flies into phase 3 as oral lupus drug soars past placeboA phase 2 trial of Beeline Medicines’ afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.fiercebiotech · 2mo ago
- Biopharma needs more data scientists. Who's getting hired?With U.S. data science jobs projected to grow 35% over the next decade, a recruiter and talent strategy director discuss the qualifications, technical skills and mindset needed to land these covete…biospace · 2mo ago
- Cancer, immune drugmakers dominate VC funding so far in 2026Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.biopharma_dive · 4mo ago
- These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.biopharma_dive · 4mo ago
comments(0)
5-min edit window · permanent after that